0OCQ Stock Chart & Stats
€0.94
€0.15(22.55%)
At close: 4:00 PM EST
€0.94
€0.15(22.55%)
Day’s Range― - ―
52-Week Range€0.71 - €1.50
Previous CloseN/A
Volume384.00
Average Volume (3M)1.45K
Market Cap
€197.86M
Enterprise Value€103.55M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding278,559,940
10 Day Avg. Volume110
30 Day Avg. Volume1,449
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€8.15M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low financial leverage and a sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces interest burden, supports funding of long-term R&D programs, and gives management optionality to pursue partnerships or staged financing without immediate solvency pressure.
Partnership-driven Revenue ModelA collaboration-focused business model aligns well with clinical-stage oncology development: upfront and milestone payments can de-risk programs, share development costs, and validate assets via partner investment. Structurally, this model can sustain R&D spend without product commercialization.
Improving Free Cash Flow TrendA near-term improvement in free cash flow, even from negative levels, suggests better cash management or timing of receipts/expenses. If sustained, this trend reduces near-term financing needs and extends runway, improving the firm's ability to advance trials and negotiate partner deals over months.
Bears Say
Persistent Losses And Negative MarginsChronic operating and net losses mean the business cannot self-fund development from operating profits. Deeply negative margins erode equity and force reliance on external funding, making the firm's long-term prospects contingent on future clinical success or recurring partner financing.
Collapsing And Volatile RevenueA near-total revenue collapse in 2025 highlights high top-line volatility and weak recurring income. Such swings undermine internal funding capacity, complicate multi-year R&D planning, and increase the company's vulnerability to delays or the non-renewal of collaboration agreements.
Consistent Cash Burn And Funding DependenceSustained negative operating and free cash flow indicates ongoing cash consumption to fund R&D. Despite low debt, the company must access external capital regularly, raising dilution and execution risk; long-term program continuity depends on successful financings or new partnership deals.
Transgene News
0OCQ FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest share price was €0.70 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €197.86M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 47 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Transgene SA dividends here
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in GB:0OCQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―